Identifying novel therapeutic agents using xenograft models of pediatric cancer Raushan T. KurmashevaPeter J. Houghton Review Article 18 May 2016 Pages: 221 - 232
The Best. First. Anti-EGFR before anti-VEGF, in the first-line treatment of RAS wild-type metastatic colorectal cancer: from bench to bedside A. ZaniboniV. Formica Review Article 18 April 2016 Pages: 233 - 244
Anti-VEGF and anti-EGFR agents open up new horizons changing the landscape for their associations Gerard Milano Letter to the Editor Open access 16 June 2016 Pages: 245 - 245
Response from Drs. Formica/Zaniboni to Dr. Milano V. FormicaA. Zaniboni Letter to the Editor 17 June 2016 Pages: 247 - 247
Rho GTPases: RAC1 polymorphisms affected platinum-based chemotherapy toxicity in lung cancer patients Ting ZouJiye YinZhaoqian Liu Original Article 14 June 2016 Pages: 249 - 258
A Phase I study of safety and pharmacokinetics of fruquintinib, a novel selective inhibitor of vascular endothelial growth factor receptor-1, -2, and -3 tyrosine kinases in Chinese patients with advanced solid tumors Junning CaoJian ZhangJin Li Original Article 14 June 2016 Pages: 259 - 269
Evaluation of the effect of necitumumab on the corrected QT interval in patients with advanced solid tumors David C. SmithJohn PowderlyPatricia LoRusso Original Article 16 June 2016 Pages: 271 - 280
Phase 1 study of abemaciclib, an inhibitor of CDK 4 and 6, as a single agent for Japanese patients with advanced cancer Yutaka FujiwaraKenji TamuraNoboru Yamamoto Original Article 16 June 2016 Pages: 281 - 288
A phase 1, dose-finding and pharmacokinetic study of gemcitabine with nab-paclitaxel in patients with metastatic breast cancer Seiji YoshitomiNaruto TairaToshiharu Mitsuhashi Original Article 17 June 2016 Pages: 289 - 294
Cystatin C as a predictor factor in patients with renal cell carcinoma treated by everolimus Lubomir BodnarRafał StecCezary Szczylik Original Article 20 June 2016 Pages: 295 - 304
Evaluation of a method for calculating carboplatin dosage in DeVIC ± R therapy (combination therapy of dexamethasone, etoposide, ifosfamide and carboplatin with or without rituximab) as a salvage therapy in patients with relapsed or refractory non-Hodgkin lymphoma Ayana TomonoKaori ItoShigeki Yamada Original Article Open access 20 June 2016 Pages: 305 - 312
Identification of clinically achievable combination therapies in childhood rhabdomyosarcoma Elliot KahenDiana YuDamon R. Reed Original Article Open access 20 June 2016 Pages: 313 - 323
Pazopanib versus sunitinib for the treatment of metastatic renal cell carcinoma patients with poor-risk features Jwa Hoon KimInkeun ParkJae Lyun Lee Original Article 21 June 2016 Pages: 325 - 332
High TUG1 expression is associated with chemotherapy resistance and poor prognosis in esophageal squamous cell carcinoma Lin JiangWenchao WangHong Yu Original Article 21 June 2016 Pages: 333 - 339
Population pharmacokinetics of bevacizumab in cancer patients with external validation Kelong HanThomas PeyretJin Jin Original Article Open access 21 June 2016 Pages: 341 - 351
Population pharmacokinetics of Reditux™, a biosimilar Rituximab, in diffuse large B-cell lymphoma Vikram GotaAshwin KaranamHari Menon Original Article 21 June 2016 Pages: 353 - 359
TACTIC: a multicentre, open-label, single-arm phase II trial of panitumumab, cisplatin, and gemcitabine in biliary tract cancer D. FerraroD. Goldsteinbehalf of the the Australasian Gastro-Intestinal Trials Group Original Article 22 June 2016 Pages: 361 - 367
Efficacy and tolerance of frontline bevacizumab-based chemotherapy for advanced non-small cell lung cancer patients: a multicenter, phase IV study of the Hellenic Oncology Research Group (HORG) A. MatikasΝ. Kentepozidison behalf of the HORG’s Lung Cancer Working Group Original Article 22 June 2016 Pages: 369 - 376
Pharmacokinetic parameters of gefitinib predict efficacy and toxicity in patients with advanced non-small cell lung cancer harboring EGFR mutations Kosuke MizoguchiYoichi NakamuraHiroshi Mukae Original Article 23 June 2016 Pages: 377 - 382
A phase II study of nanoparticle albumin-bound paclitaxel plus carboplatin as the first-line therapy in elderly patients with previously untreated advanced non-small cell lung cancer Yusuke OkumaYukio HosomiShinichiro Mikura Original Article 23 June 2016 Pages: 383 - 388
Impact of capecitabine and S-1 on anticoagulant activity of warfarin in patients with gastrointestinal cancer Tsuyoshi HataToshihiro KudoTaroh Satoh Original Article 23 June 2016 Pages: 389 - 396
Panitumumab in combination with irinotecan plus S-1 (IRIS) as second-line therapy for metastatic colorectal cancer Toshi TakaokaTetsuo KimuraTetsuji Takayama Original Article 24 June 2016 Pages: 397 - 403
A phase I study of BI 811283, an Aurora B kinase inhibitor, in patients with advanced solid tumors Klaus MrossHeike RichlyMax E. Scheulen Original Article Open access 27 June 2016 Pages: 405 - 417
New insights into renal toxicity of the B-RAF inhibitor, vemurafenib, in patients with metastatic melanoma Cécile TeumaMarie Perier-MuzetStéphane Dalle Original Article 01 July 2016 Pages: 419 - 426
Association of concurrent acid-suppression therapy with survival outcomes and adverse event incidence in oncology patients receiving erlotinib Lisa H. LamEdmund V. CapparelliRazelle Kurzrock Original Article 02 July 2016 Pages: 427 - 432
Lack of pharmacokinetic drug–drug interaction between ramucirumab and paclitaxel in a phase II study of patients with advanced malignant solid tumors Laura Q. M. ChowDavid C. SmithLing Gao Original Article Open access 05 July 2016 Pages: 433 - 441